Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:31 2022-11-25 am EST
49.10 CHF   -1.31%
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ BASILEA PHARMACEUTICA AG
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
GL
10/26Basilea Pharmaceutica : Updated October 26, 2022
PU
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
GL
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
AQ
10/13Basilea announces late breaking presentation on the successfully completed ERADICATE ph..
GL
10/13Basilea announces late breaking presentation on the successfully completed ERADICATE ph..
AQ
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/08Basilea announces sale of preclinical oncology program to Nodus Oncology
GL
09/07Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-di..
GL
08/16Basilea Pharmaceutica : Updated August 16, 2022
PU
08/16Basilea reports strong financial half-year results and progress in the implementation o..
GL
07/12Basilea announces Zevtera« (ceftobiprole) marketing authorization in Brazil
GL
07/12Basilea announces Zevtera« (ceftobiprole) marketing authorization in Brazil
AQ
06/27Basilea reports progress on the implementation of its strategy to focus on anti-infecti..
GL
06/24Basilea announces approval for additional formulation of antifungal Cresemba« (isavucon..
GL
06/24Basilea announces approval for additional formulation of antifungal Cresemba« (isavucon..
AQ
06/17Cresemba« sales in Asia Pacific region trigger sales milestone payment to Basilea from ..
GL
06/17Cresemba« sales in Asia Pacific region trigger sales milestone payment to Basilea from ..
AQ
04/27Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase..
AQ
04/13Basilea shareholders approve all proposals of the board of directors at the annual gene..
GL
04/13Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and ..
AQ
03/30Basilea Pharmaceutica : Updated March 30, 2022
PU
03/16Basilea Pharmaceutica : Shareholder letter EN
PU
02/21Basilea Pharmaceutica : Updated Februaryá 21, 2022
PU
02/15Basilea Pharmaceutica : Updated Februaryá 15, 2022
PU
01/24Basilea Pharmaceutica : Updated January 24, 2022
PU
01/13Basilea announces approval of antifungal Cresemba« (isavuconazole) for invasive aspergi..
AQ
01/11Basilea Pharmaceutica : Updated January 11, 2022
PU
01/10Basilea Pharmaceutica : Updated January 10, 2022
PU
01/07Basilea Pharmaceutica : Updated January 07, 2022
PU
01/07Strong Cresemba« (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million s..
AQ
01/06Basilea Pharmaceutica : Updated January 06, 2022
PU
2021Basilea receives USD 10 million milestone payment related to approval of antifungal Cre..
AQ
2021Basilea Pharmaceutica : Updated December 17, 2021
PU
2021Continued strong Cresemba« (isavuconazole) sales by Pfizer trigger USD 10 million sales..
AQ
2021Basilea Pharmaceutica : Updated November 16, 2021
PU
2021Basilea Pharmaceutica : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
2021Basilea Pharmaceutica : reports strong financial results for half-year 2021 with significa..
AQ
2021Basilea Pharmaceutica : partner Asahi Kasei Pharma prepares NDA filing for the marketing a..
AQ
2021Basilea Pharmaceutica : announces distribution agreement with JSCáLancet for antibiotic Ze..
AQ
2021Basilea Pharmaceutica : shareholders approve all proposals of the board of directors at th..
AQ
2021Basilea Pharmaceutica : successfully placed 1 million new registered shares, raising gross..
AQ
2020Basilea Pharmaceutica : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020Basilea Pharmaceutica : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020Basilea Pharmaceutica : announces approval of antibiotic Zevtera« in China to treat commun..
AQ
2020Basilea Pharmaceutica : announces approval of antibiotic Zevtera« in China to treat commun..
AQ
2020Basilea announces approval of antibiotic Zevtera« in China to treat community-acquired ..
GL
2020Basilea Pharmaceutica : announces Clinical Trial Collaboration and Supply Agreement with E..
AQ
2020Basilea Pharmaceutica : announces Clinical Trial Collaboration and Supply Agreement with E..
AQ
2020Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and ..
GL
2020Basilea Pharmaceutica : presents preclinical data on anti-angiogenic activity of derazanti..
AQ
2020Basilea Pharmaceutica : presents preclinical data on anti-angiogenic activity of derazanti..
AQ
2020Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 20..
GL
2020Basilea Pharmaceutica : reports interim results from phase 1/2 study FIDES-02 exploring de..
AQ
2020Basilea Pharmaceutica : reports interim results from phase 1/2 study FIDES-02 exploring de..
AQ
2020Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in..
GL
2020Basilea Pharmaceutica : reports pooled efficacy data for derazantinib in iCCA patients wit..
AQ
2020Basilea Pharmaceutica : reports pooled efficacy data for derazantinib in iCCA patients wit..
AQ
2020Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene ..
GL
2020Basilea Pharmaceutica : initiates targeted biomarker-driven phase 2 study with lisavanbuli..
AQ
2020Basilea Pharmaceutica : initiates targeted biomarker-driven phase 2 study with lisavanbuli..
AQ
2020Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients..
GL
2020Basilea Pharmaceutica : starts phase 1/2 study FIDES-03 with derazantinib in patients with..
AQ
2020Basilea Pharmaceutica : starts phase 1/2 study FIDES-03 with derazantinib in patients with..
AQ
2020Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric canc..
GL
2020Basilea Pharmaceutica : reports data from poster presentations at ESMO Virtual Congress 20..
AQ
2020Basilea Pharmaceutica : reports data from poster presentations at ESMO Virtual Congress 20..
AQ
2020Basilea reports data from poster presentations at ESMO Virtual Congress 2020
GL
2020Basilea reports strong financial results for half-year 2020, progress in R&D portfolio ..
GL
2020Basilea Pharmaceutica : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020Basilea reports acceptance for regulatory review of Pfizer's marketing authorization ap..
GL
2020Basilea announces completion of its transaction involving a partial repurchase of its e..
GL
1  2  3  4  5Next
Upcoming event on BASILEA PHARMACEUTICA AG